Compare LYEL & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | RM |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.4M | 396.7M |
| IPO Year | 2021 | 2012 |
| Metric | LYEL | RM |
|---|---|---|
| Price | $25.25 | $36.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $16.67 | ★ $30.00 |
| AVG Volume (30 Days) | 44.4K | ★ 53.0K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 3.31% |
| EPS Growth | N/A | ★ 71.26 |
| EPS | N/A | ★ 4.13 |
| Revenue | $41,000.00 | ★ $610,145,000.00 |
| Revenue This Year | N/A | $16.34 |
| Revenue Next Year | N/A | $7.05 |
| P/E Ratio | ★ N/A | $8.79 |
| Revenue Growth | N/A | ★ 9.60 |
| 52 Week Low | $7.65 | $25.41 |
| 52 Week High | $25.74 | $46.00 |
| Indicator | LYEL | RM |
|---|---|---|
| Relative Strength Index (RSI) | 69.41 | 42.44 |
| Support Level | $20.59 | $36.84 |
| Resistance Level | $25.20 | $37.73 |
| Average True Range (ATR) | 2.03 | 1.32 |
| MACD | 0.48 | 0.03 |
| Stochastic Oscillator | 95.62 | 23.58 |
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.